Heart Failure Pharmacotherapy: The Four Pillars in Practice
A practical summary of guideline-directed medical therapy for HFrEF — the four pillars, how to initiate, and what order to titrate when the patient is in clinic.
- Published
- 22 Apr 2026
- Read time
- 3 min read
Guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) has converged across ESC, AHA/ACC/HFSA, and NICE on four mortality-reducing drug classes — the "four pillars" — to be started early and up-titrated in parallel rather than sequentially.
The four pillars
| Pillar | Class | Examples |
|---|---|---|
| 1 | ACEi / ARB / ARNi | Ramipril, candesartan, sacubitril-valsartan |
| 2 | Beta-blocker | Bisoprolol, carvedilol, nebivolol |
| 3 | Mineralocorticoid receptor antagonist (MRA) | Spironolactone, eplerenone |
| 4 | SGLT2 inhibitor | Dapagliflozin, empagliflozin |
Each pillar independently reduces all-cause mortality. The mortality reduction is additive, not redundant. The 2021 ESC guideline replaced the older stepwise approach with rapid combined initiation: start all four (or at least three) within weeks of diagnosis, then titrate.
When to start each
Diagnosis confirmed (echo EF ≤40%) — start within days
- ARNi or ACEi at low dose
- Beta-blocker at low dose (only if euvolaemic — see note below)
- SGLT2 inhibitor at standard dose (no titration needed)
Within 2-4 weeks
- MRA added once renal function and potassium confirmed safe
Note on sequence vs. simultaneous
The traditional sequence (ACEi → BB → MRA → ARNi) has been replaced. Recent observational and trial-emulation work (STRONG-HF, EMPULSE) suggests:
- Faster initiation = better outcomes
- "Low doses of all four" beats "target dose of one" in head-to-head trajectory
Evidence
STRONG-HF (2022) randomised post-discharge HF patients to high-intensity rapid up-titration vs. usual care. The intervention arm reached full doses by 2 weeks and had a 34% lower rate of 180-day death or HF readmission (HR 0.66, 95% CI 0.50-0.86).
Starting doses and targets
Bisoprolol1.25 mgPO Ramipril2.5 mgPO Sacubitril-valsartan24/26 mgPO Spironolactone12.5-25 mgPO Dapagliflozin10 mgPOPractical clinic checklist
- Confirm HFrEF. Echo EF ≤40%. (HFmrEF and HFpEF benefit from SGLT2i; ARNi has equivocal data; MRA partial benefit.)
- Check renal function and potassium before MRA. eGFR ≥30, K+ ≤5.0.
- Confirm euvolaemia before starting beta-blocker — do not initiate in active decompensation.
- Education — symptoms to monitor, weight diary, sick-day rules, vaccination.
- Up-titrate every 2-4 weeks, halving the interval if remote monitoring available.
Red flag
Initiating SGLT2 inhibitors during DKA, severe AKI, or while NBM peri-operatively risks euglycaemic DKA. Hold dapagliflozin/empagliflozin 24-48 hours pre-op and during acute illness.
When the patient pushes back
Common reasons treatment doesn't get to target:
- Symptomatic hypotension → consolidate dosing times, reduce diuretic first.
- Hyperkalaemia → review concomitant ACEi + MRA dosing, consider potassium binders (patiromer, sodium zirconium cyclosilicate) rather than dropping MRA.
- Worsening renal function → a 30% creatinine rise on starting ACEi/MRA is expected and not a stop signal; reassess at 2 weeks.
- Bradycardia on beta-blocker → consider ivabradine if HR >70 in sinus.
Clinical pearl
The single best predictor of who reaches GDMT targets is who sees a heart-failure nurse-specialist regularly. Refer at diagnosis, not at decompensation.
Key points
- HFrEF GDMT is four pillars, initiated rapidly and in parallel.
- Mortality reduction is additive; under-treatment is the rule, not the exception.
- Beta-blockers require euvolaemia at initiation; SGLT2 needs sick-day rules.
- Heart-failure nurse-specialist input transforms titration trajectory.
References
- [1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Link
- [2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032. Link
- [3]NICE NG106. Chronic heart failure in adults: diagnosis and management. Updated 2023. Link
About the author
Dr. Imani OkoroVerifiedVerified medical practitioner
MBBS, MRCP, PhD
Consultant cardiologist with a research interest in heart failure pharmacotherapy and remote monitoring. Edits the cardiology stream for MedSchool.
More in Cardiology
Managing Acute Decompensated Heart Failure on the Ward
A practical ward-level framework for the patient with acute decompensated heart failure — assessment, diuresis, and the early decisions that matter most.
Remote Ischaemic Preconditioning: A Clinical Evidence Update
A decade after promising mechanistic and pilot data, where does remote ischaemic preconditioning actually stand in cardiac and non-cardiac surgery?
Omega-3s in Cardiovascular Prevention: What the Evidence Says
A pragmatic synthesis of where omega-3 fatty acid supplementation sits in cardiovascular prevention after REDUCE-IT, STRENGTH, and the secondary-prevention meta-analyses.